Just In: Actinium Pharmaceuticals (NYSE: ATNM) Makes Approx. 15% Early Move as Major Collaboration Is Announced

*Sponsored Market Crux Announces Actinium Pharmaceuticals, Inc. (NYSE: ATNM) As Its Next Potential Breakout Idea. Coverage On Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Begins This Morning—Thursday March 20, 2025. And Here’s Why… With A Market Cap Under $40M And A Float Below 32M Shares, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Fits A Structure  Tied To Higher Growth Potential. Wall Street Analysts Have Issued Bullish Targets On Actinium Pharmaceuticals, Inc. (NYSE: ATNM), Highlighting  Significant Upside Potential. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Has Moved Approx. 26%  Over 10 Sessions—Surpassing Key Moving Averages. With Hundreds Of Patents, Actinium Pharmaceuticals, Inc. (NYSE: ATNM)   Has Secured A Strong Position In Targeted Radiotherapy. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is Positioned In A Fast-Growing Market With The Global Cancer Immunotherapy Market Forecasted Top $338.40B Within The Next Decade Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is Topping Our Watchlist  This Morning—Keep Reading To Get Caught Up To Speed. March 20, 2025 Dear Reader, Do you have this on your screen yet? A breaking development from Actinium Pharmaceuticals, Inc. (NYSE: ATNM) just hit—a major collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to further expand Actimab-A’s potential as a backbone AML therapy.  The study will focus on new targeted treatment combinations, including FLT3 and menin inhibitors, while testing its effectiveness in patient-derived samples. At the same time, (ATNM) moved approximately 15% in the early session from $1.19 to $1.38, lighting up Multiple Bullish Indicators on TradingView while breaking through several key moving averages. With trials advancing and new studies evaluating Actimab-A with KEYTRUDA® and OPDIVO®, this latest move signals big things ahead for Actinium Pharmaceuticals, Inc. (NYSE: ATNM).  If you missed my earlier coverage, keep reading to see why we’re so excited about  Actinium Pharmaceuticals, Inc. (NYSE: ATNM) right now.  When analysts start setting aggressive targets, there’s usually a reason. This company has been advancing a new radiotherapy treatment that’s starting to make waves in oncology circles.  The latest analyst coverage suggests things are heating up. See why Actinium Pharmaceuticals, Inc. (NYSE: ATNM) just landed at the top of our radar this morning. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Crosses Key Moving Averages—Potential For Continued Momentum Is Building… In just 10 recent sessions, (ATNM) has moved approximately 26%, from $1.02 on 3/4/2025 to $1.30 on 3/17/2025. This upward move has pushed (ATNM) past several key moving averages including the 5-Day at $1.22, 20-Day at $1.1595 and 50-Day at $1.2044. With its 100-Day and 200-Day moving averages at $1.3424 and $2.8559, respectively, we have all eyes on Actinium Pharmaceuticals, Inc. (NYSE: ATNM) this morning. Keep reading to see why we have all eyes on (ATNM) this morning… Analyst Target Suggests Over 331% Upside Potential… Wall Street analysts have begun recognizing Actinium Pharmaceuticals, Inc. (NYSE: ATNM)’s potential, with multiple firms issuing strong targets: -Maxim Group: Analyst Jason McCarthy, Ph.D., has a $5 target that was published in a March 14, 2025 report, which suggests a 331% upside potential move from today’s $1.16 range . -HC Wainwright & Co.: Senior Healthcare Analyst Joseph Pantginis, Ph.D., reaffirmed a $4 target, as reported by Benzinga, which suggests 244% upside potential. -Stephens, Inc.: Analyst Sudan Loganathan, Ph.D., maintained an "Overweight" rating with a $5 target. Big names may dominate the headlines, but it’s the small and micro-cap companies flying under the radar that often make the biggest moves when the right catalyst hits. With a market cap under $40M and fewer than 32M shares in the float, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) operates with the kind of tight structure that has historically fueled rapid growth when momentum builds.  Now, with analysts setting targets as high as $5, signaling potential upsides of 244% to 331%, this under-the-radar biotech may not stay unnoticed for long. Keep reading to see why Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is topping our watchlist this morning. About Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a pioneer in targeted radiotherapy for oncology.  The company is advancing Actimab-A, a CD33-targeting therapeutic designed as a backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies.  Actimab-A leverages Actinium-225 (Ac-225), a mutation-agnostic alpha-emitter radioisotope, to deliver targeted radiotherapy directly to cancer cells. Key Developments: -Actimab-A has shown high rates of Complete Remission (CR) and measurable residual disease (MRD) negativity in relapsed and refractory AML (r/r AML) patients. -The candidate is advancing to a pivotal Phase 2/3 clinical trial, with potential implications for significantly improved patient outcomes. -Actinium is working with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) to expand Actimab-A’s applications. Beyond AML, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is also developing Actimab-A as a combination therapy for solid tumors, particularly in combination with PD-1 checkpoint inhibitors, such as: -KEYTRUDA® (Merck & Co.) -OPDIVO® (Bristol Myers Squibb) Actinium Pharmaceuticals (NYSE: ATNM) Targets a Booming  Immunotherapy Industry… The global cancer immunotherapy market is expanding rapidly, driven by continuous innovation and increasing adoption of advanced treatments.  Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is advancing clinical trials to evaluate Actimab-A in combination with PD-1 inhibitors for solid tumors, aiming to enhance the effectiveness of leading immunotherapies like KEYTRUDA® and OPDIVO® by targeting Myeloid-Derived Suppressor Cells (MDSCs)—a known factor in treatment resistance. Ongoing trials will compare Actimab-A + KEYTRUDA® vs. KEYTRUDA® alone and Actimab-A + OPDIVO® vs. OPDIVO® alone, with a focus on Head and Neck Squamous Cell Carcinoma (HNSCC) and Non-Small Cell Lung Cancer (NSCLC).  These studies will measure Overall Response Rate (ORR), Progression-Free Survival (PFS), Overall Survival (OS), and MDSC depletion patterns.   With initial proof-of-concept data expected in late 2025, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is approaching a key milestone. This comes as the global cancer immunotherapy market is projected to grow from $136.39B in 2025 to approximately $338.40B by 2034, with the U.S. market expected to expand from $36.54B in 2024 to $106.35B by 2034.  With increasing demand for more precise, effective immunotherapies, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is positioning itself within a rapidly growing sector. 7 Reasons Why Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Is Topping Our Watchlist This Morning… 1. Under The Radar: With a market cap under $40M and fewer than 32M shares in the float, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) has a structure that has historically been associated with higher potential for growth as interest builds. 2. Analyst Backing: Multiple Wall Street firms, including Maxim Group ($5), HC Wainwright & Co. ($4), and Stephens, Inc. ($5), have issued bullish targets, signaling what they see as a significant upside potential for Actinium Pharmaceuticals, Inc. (NYSE: ATNM) as attention on its developments grows. 3. Recent Momentum: Over a recent 10 sessions stretch, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) has moved approximately 26%, surpassing several key moving averages along the way, which could suggest the potential for bullish momentum. 4. Innovative Radiotherapy Approach: A mutation-agnostic targeted radiotherapy utilizing Actinium-225 is being developed to deliver radiation directly to cancer cells while minimizing damage to surrounding healthy tissue—an approach that Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is working to advance. 5. Upcoming Clinical Data: Key proof-of-concept clinical data is expected to be released in late 2025, with trials assessing targeted radiotherapy in combination with PD-1 inhibitors like KEYTRUDA® and OPDIVO®—a development that could be pivotal for Actinium Pharmaceuticals, Inc. (NYSE: ATNM). 6. Institutional Collaborations & Intellectual Property Strength: Through a high-profile agreement with the National Cancer Institute (NCI) under a CRADA, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is advancing its research while securing hundreds of patents, including exclusive rights to Actinium-225 production—solidifying its leadership in targeted radiotherapy. 7. Positioned in a Fast-Growing Market: The global cancer immunotherapy market is forecasted to grow from $136.39B in 2025 to approximately $338.40B by 2034, with the U.S. market expected to reach $106.35B. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is advancing trials in this rapidly expanding space. Put Actinium Pharmaceuticals, Inc. (NYSE: ATNM) On Your  Radar This Morning… Not every biotech name earns a spot at the top of our watchlist—but Actinium Pharmaceuticals, Inc. (NYSE: ATNM) has been making moves that demand attention this morning. With the potential for bullish momentum unfolding, an approximate 26% move in recent sessions, and multiple Wall Street analysts setting aggressive targets, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is one under the radar company to keep an eye on. Its upcoming clinical data, high-profile collaborations, and strong patent portfolio only add to the case.  When a company with this kind of structure starts gaining momentum, it’s worth paying attention. That’s why we have all eyes on (ATNM) this morning.  Consider taking a look at (ATNM) while it’s still early. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) moved approximately 15% in the early session from $1.19 to $1.38, lighting up Multiple Bullish Indicators on TradingView while breaking through several key moving averages. Do you have (ATNM) on your screen yet?  Also—keep an out for my next update—it could be on its way to you at any time. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 03/20/2025 and ending on 03/20/2025 to publicly disseminate information about (ATNM:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (ATNM:US). Please see important disclosure information here: https://marketcrux.com/disclosure/atnm/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice